# Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

> **NCT03387150** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 124 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC07-523LS
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03387150
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2020-12-07
- **Final completion:** 2020-12-07
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387150, "Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03387150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*